Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Background: Patients with Hemophilia A or B with and without inhibitors lack treatment options that are fast and easy to use for treating acute bleeding. Currently, their only options are intravenous administration of replacement or bypass therapies. Marzeptacog alfa (activated) (MarzAA) is a novel...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.2420-2420
Hauptverfasser:	Del Greco, Frank, Neuman, Linda, Levy, Howard, Reckless, Jill, Knudsen, Tom, Blouse, Grant E.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!